Scaffold Hopping-Guided Design of Novel PIM-1 Inhibitors with Anticancer Activities

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Pharmacology

Background:

• PIM kinases are serine/threonine kinases crucial for cell proliferation, apoptosis, and metabolism.
• Dysregulation of PIM kinases is implicated in various cancers, making them attractive therapeutic targets.
• Novel inhibitors are needed to effectively target PIM kinases in cancer treatment.

Purpose of the Study:

• To design and synthesize novel PIM-1 kinase inhibitors using a scaffold-hopping strategy.
• To evaluate the inhibitory activity and antitumor effects of the synthesized compounds.
• To assess the drug-like properties and stability of the lead compound.

Main Methods:

• Scaffold-hopping strategy for inhibitor design.
• Synthesis and structural optimization of novel compounds.
• Biochemical assays to determine IC50 values against PIM-1 kinase.
• Molecular docking to predict binding interactions.
• In vitro antitumor assessment using hematological tumor cell lines.
• Evaluation of drug-like properties and stability.

Main Results:

• A series of novel PIM-1 kinase inhibitors were synthesized.
• Compound C2 demonstrated high inhibitory activity against PIM-1 kinase (IC50 = 33.02 ± 1.31 nM).
• Molecular docking confirmed stable binding of C2 to the PIM-1 active site.
• Compound C2 significantly inhibited MM.1S hematological tumor cell proliferation (IC50 = 1.87 μM).
• C2 exhibited favorable drug-like properties and good stability in simulated physiological conditions.

Conclusions:

• The study identified novel PIM-1 kinase inhibitors with significant anticancer potential.
• Compound C2 is a promising lead compound for developing PIM-1-targeted anticancer therapeutics.
• Further optimization of these compounds could lead to effective cancer treatments.